brentuximab vedotin for Hodgkin Disease

Phase-Based Progress Estimates
The Montreal Children's Hospital of the MUHC, Montreal, Canada
Hodgkin Disease
brentuximab vedotin - Biological
< 65
All Sexes
Eligible conditions

Study Summary

This study is evaluating whether a combination of two drugs may help treat Hodgkin's lymphoma.

See full description

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Hodgkin Disease

Study Objectives

This trial is evaluating whether brentuximab vedotin will improve 9 secondary outcomes in patients with Hodgkin Disease. Measurement will happen over the course of Up to 12 weeks.

Up to 12 weeks
Overall Response Rate (ORR) after 4 cycles of nivolumab + brentuximab vedotin treatment
Up to 5 years
Complete Metabolic Response (CMR) rate at any time prior to radiation therapy
Complete Metabolic Response (CMR) rate prior to HDCT/ASCT
Duration of Response (DOR)
Event Free Survival (EFS)
Incidence of clinically significant abnormalities in general laboratory tests of nivolumab (BMS-936558) and brentuximab when given in combination.
Incidence of clinically significant vital sign measurements of nivolumab (BMS-936558) and brentuximab when given in combination.
Incidence of serious and non-serious adverse events of nivolumab (BMS-936558) and brentuximab when given in combination.
Progression Free Survival Rate (PFSR)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Hodgkin Disease

Trial Design

2 Treatment Groups

brentuximab vedotin + bendamustine
1 of 2
Nivolumab + brentuximab vedotin
1 of 2
Experimental Treatment

This trial requires 72 total participants across 2 different treatment groups

This trial involves 2 different treatments. Brentuximab Vedotin is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

brentuximab vedotin + bendamustine
Nivolumab + brentuximab vedotin
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
Brentuximab vedotin
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 5 years for reporting.

Closest Location

The Montreal Children's Hospital of the MUHC - Montreal, Canada

Eligibility Criteria

This trial is for patients born any sex aged 65 and younger. You must have received 1 prior treatment for Hodgkin Disease. There are 3 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Classic Hodgkin Lymphoma (cHL), relapsed or refractory
Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
One prior anti-cancer therapy that did not work

Patient Q&A Section

How many people get hodgkin disease a year in the United States?

"Between 27,000 and 40,000 New York sufferers are diagnosed with the disease each year, making Hodgkin disease America's most serious haematological malignancy. Although childhood leiomyosarcoma is more common, Hodgkin's disease remains the most frequently encountered malignancy of all haematopoietic tumours in Australia." - Anonymous Online Contributor

Unverified Answer

What causes hodgkin disease?

"Hodgkin disease affects about a third of patients with one of the main B lymphocyte disorders which is the malignant transformation of the B lymphocyte. The cause of Hodgkin lymphoma is uncertain. It is probably a group of related diseases of the B lymphocyte system. This article describes the history, investigation, classification and treatment of the disorder." - Anonymous Online Contributor

Unverified Answer

What are common treatments for hodgkin disease?

"Complete response after remission with some salvage therapy are achievable in many patients with Hodgkin disease. In children with Stage IV disease, and in patients with excellent responders to initial chemotherapy, many achieve long-term complete remission. In children with Stage III disease or relapsed or refractory disease, a more aggressive approach with high doses of chemotherapy and autologous stem cell transplant is needed. In more advanced disease, combination chemotherapy with alkylating agents, autologous stem cell transplant, or a high-dose therapy with a myelotoxic tyrosine kinase inhibitor is warranted. Most of the agents used in the current generation produce a response, but relapse is common." - Anonymous Online Contributor

Unverified Answer

What are the signs of hodgkin disease?

"There are several signs and symptoms affecting the internal and external genitalia of males and females. Patients with genital lesions should be screened for other disorders and treated appropriately. Physicians and surgeons should be aware of the signs and symptoms involving the external genitalia when performing surgery on patients. When evaluating patients, attention must be paid to detecting and treating other medical conditions that present similar symptoms." - Anonymous Online Contributor

Unverified Answer

What is hodgkin disease?

"The incidence of HD is around 20-25 per 100,000 persons, however incidence rates have stabilised and there is increasing survival. The incidence is highest in males, those diagnosed with AIDS and those who are in the 20-30 year age group. HD was first described by Dr. Robert Hodgkin in 1886.\n" - Anonymous Online Contributor

Unverified Answer

Can hodgkin disease be cured?

"Hodgkin disease cannot be cured. However, in select patients with early stage disease, early diagnosis and treatment can reduce the chances of early cancer related death." - Anonymous Online Contributor

Unverified Answer

What does brentuximab vedotin usually treat?

"Although it is difficult to differentiate between SIP and CD30+ T-cell lymphomas based on clinical features, histopathological or molecular findings, the treatment with brentuximab vedotin is quite effective. Treatment with other drugs (such as platinum, etoposide, and anthracycline) or new chemotherapeutic agents and/or biologic drugs (such as TSHR-blocking agents (like abemesetron) and anti-PD-1 agents like alemtuzumab or ipilimumab) may be indicated when the first regimen fails." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets hodgkin disease?

"Hodgkin disease affects both males and females. The average age for being diagnosed with HD is 59 years. A male to female ratio of 1.01:1, with a median age of 61 years. There will be more boys diagnosed, due to the higher incidence of HD in boys. It is estimated that 1.2% of children, who develop the disease by the age of 15, will be diagnosed with HD, making it the most prevalent childhood lymphoid cancers of all. The number of children who have succumbed to HD also increase, as well. The median survival of HD is 2 years." - Anonymous Online Contributor

Unverified Answer

Does hodgkin disease run in families?

"The frequency of HID in families with two affected family members is not significantly higher than in the background prevalence of HID in the UK population. Thus it seems likely that HID will also be diagnosed in two members of the same family at some point in time. This may, for a variety of reasons, dissuading the patient with HID from trying to find evidence of their disease in themselves through a family history." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of brentuximab vedotin?

"Brentuximab vedotin had frequent adverse events, particularly diarrhea, vomiting and/or dehydration. The observed symptoms occurred mainly during the initial period (< or =3 weeks) of the treatment." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for hodgkin disease?

"Clinicing patients and their families with a clinical trial protocol is highly beneficial in the patient's interest. The study results may have a profound impact on their ability to deal with any future treatment challenges." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for hodgkin disease?

"For the hodgkin disease patients from Sweden, who received treatment according to the guidelines, the five-year survival rate was 88% and the 10-year survival rate was 75.7%. The five-month survival rate was 84.5% and the five-year survival rate was 78.9%. Because a lower control rate can lead to underreporting, we cannot give an exact survival rate for the patients who were not treated according to the guidelines. It is also likely that other treatment groups or units, which received a higher control rate due to different management, have a higher survival rate than the controlled units." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Hodgkin Disease by sharing your contact details with the study coordinator.